Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report

Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report

Advanced hepatocellular carcinoma (HCC) is a highly lethal disease, mainly due to the late stage at diagnosis and its rapid progression. Although patients with advanced HCC can choose targeted therapy or chemotherapy, overall, the treatment response rate is extremely low and the average survival tim...

Full description

Bibliographic Details
Main Authors:	Chenxi Liu, Jie Shao, Yanbing Dong, Qiuping Xu, Zhengyun Zou, Fangjun Chen, Jing Yan, Juan Liu, Shuangshuang Li, Baorui Liu, Jie Shen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Immunology
Subjects:	hepatocellular carcinoma neoantigen reactive T cells immunotherapy tomotherapy benefit
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.685126/full

Similar Items

The Efficacy and Safety of Hypofractionated Radiation Therapy With Tomotherapy for Advanced or Recurrent Hepatocellular Carcinoma
by: Jie Shen, et al.
Published: (2021-05-01)

Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy
by: Yicheng Zhu, et al.
Published: (2021-06-01)

Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
by: Daniel J. Verdon, et al.
Published: (2021-08-01)

The Role of Neoantigens in Cancer Immunotherapy
by: Yueting Zhu, et al.
Published: (2021-08-01)

Neoantigen vaccine: an emerging tumor immunotherapy
by: Miao Peng, et al.
Published: (2019-08-01)

Targeting neoantigens for cancer immunotherapy
by: Xuan Zhao, et al.
Published: (2021-07-01)

Mutation-Derived Neoantigens for Cancer Immunotherapy
by: John C. Castle, et al.
Published: (2019-08-01)

Cancer neoantigen: Boosting immunotherapy
by: Peijia Xu, et al.
Published: (2020-11-01)

High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy
by: Angela Mauriello, et al.
Published: (2019-11-01)

Neoantigen: A New Breakthrough in Tumor Immunotherapy
by: Zheying Zhang, et al.
Published: (2021-04-01)

Progress in Neoantigen Targeted Cancer Immunotherapies
by: Xue-Jiao Han, et al.
Published: (2020-07-01)

Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients
by: Annacarmen Petrizzo, et al.
Published: (2018-10-01)

Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
by: Thomas C. Wirth, et al.
Published: (2017-12-01)

Determinants for Neoantigen Identification
by: Andrea Garcia-Garijo, et al.
Published: (2019-06-01)

Tumor neoantigens: from basic research to clinical applications
by: Tao Jiang, et al.
Published: (2019-09-01)

NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy
by: Jiaqi Xia, et al.
Published: (2021-04-01)

The Neoantigen Landscape of Mycosis Fungoides
by: Arunima Sivanand, et al.
Published: (2020-11-01)

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
by: Yugang Guo, et al.
Published: (2018-07-01)

The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
by: Terhi Karpanen, et al.
Published: (2017-12-01)

A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment
by: Zheling Chen, et al.
Published: (2021-08-01)

Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy
by: Xiaomei Zhang, et al.
Published: (2019-12-01)

Neoantigens in Hematologic Malignancies
by: Melinda A. Biernacki, et al.
Published: (2020-02-01)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
by: Peipei Wang, et al.
Published: (2021-04-01)

Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer
by: Chi Zhou, et al.
Published: (2020-12-01)

The Clinical Application of Neoantigens in Esophageal Cancer
by: Yi-Min Gu, et al.
Published: (2021-07-01)

Identifying Potential Neoantigens for Cervical Cancer Immunotherapy Using Comprehensive Genomic Variation Profiling of Cervical Intraepithelial Neoplasia and Cervical Cancer
by: Chaohui Bao, et al.
Published: (2021-06-01)

Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses
by: Wei Zhang, et al.
Published: (2021-04-01)

Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications
by: Lin Tang, et al.
Published: (2021-07-01)

Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies
by: Vanessa M. Tubb, et al.
Published: (2018-07-01)

Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth
by: Luigi Aurisicchio, et al.
Published: (2019-02-01)

Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges
by: Fei Lu, et al.
Published: (2021-05-01)

Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma
by: Chen, X., et al.
Published: (2022)

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators
by: Yong Qin, et al.
Published: (2017-06-01)

Characterization of Neoantigen Load Subgroups in Gynecologic and Breast Cancers
by: Yue Zhu, et al.
Published: (2020-07-01)

pTuneos: prioritizing tumor neoantigens from next-generation sequencing data
by: Chi Zhou, et al.
Published: (2019-10-01)

Progress and challenges of personalized neoantigens in the clinical treatment of tumors
by: Hongyu Zhang, et al.
Published: (2020-06-01)

A novel neoantigen discovery approach based on chromatin high order conformation
by: Yi Shi, et al.
Published: (2020-08-01)

A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer
by: Spencer D. Martin, et al.
Published: (2018-01-01)

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
by: Di Wu, et al.
Published: (2020-07-01)

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
by: Elena Tondini, et al.
Published: (2019-11-01)